Why the study?
Does losartan reduce myocardial fibrosis and left ventricular chamber stiffness in patients with essential hypertension?
Does losartan reduce myocardial fibrosis and left ventricular chamber stiffness in patients with essential hypertension?
Losartan may improve left ventricular chamber stiffness by regressing myocardial fibrosis in patients with essential hypertension.
Answers are grounded in this paper and cite their sources.
Losartan may improve LV stiffness via fibrosis regression in hypertension; leaves open confirmation in randomized outcome trials.
These findings show a strong association between myocardial collagen content and LV chamber stiffness in patients with essential hypertension. Our results also suggest that the ability of losartan to induce regression of severe myocardial fibrosis is associated with diminution of myocardial stiffness in hypertensive patients.
No takes yet. Share an insight, caveat, or question.
Dı́ez et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: